Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 6 (Table of Contents)
Published: 21 Jun-2011
DOI: 10.3833/pdr.v2011.i6.1485 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Boehringer Ingelheim has licensed the global rights to Zealand Pharma’s dual-acting glucagon and GLP-1 (glucagon-like peptide-1) agonists for the treatment of type 2 diabetes and obesity...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS